BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200730T191500
DTEND;TZID=Africa/Nairobi:20200730T203000
DTSTAMP:20260425T071422
CREATED:20210810T101728Z
LAST-MODIFIED:20250622T142511Z
UID:5839-1596136500-1596141000@kesho-kenya.org
SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
END:VEVENT
END:VCALENDAR